Lucky us: Even though the ECR 2017 has already ended we still got the chance for a short interview with Dr. Pereira afterwards. At the ECR, he spoke about "Registries, trials and evidence base". Have a look at the interview:
Interview with Professor Dr. med. Philippe L. Pereira
Director of the Clinic of Radiology, Minimally Invasive Therapies and Nuclear Medicine.
SLK-Clinics Heilbronn GmbH
Academic Hospital of Ruprecht-Karls-University Heidelberg
Faculty of Eberhards-Karls-University Tübingen
DocCheck: Could you give us a brief update on new possibilities of image-guided interventions in the liver?
Dr. Pereira: Improvement in the IT technologies is a great benefit especially for Radiology. New technologies include targeted liver tumor therapies with drug eluted microparticles, interstitial radiation therapy and faster and effective thermal ablation modalities.
DocCheck: With regard to the current available treatment methods and possibilities, where do you see the challenges in further improving treatment?
Dr. Pereira: Key in oncology is the multidisciplinary aspect. We will cure more patients by combining treatments and multidisciplinarity, nobody alone has the solution for these complex diseases.
DocCheck: Do you think minimally invasive treatment will replace most of the surgical approaches?
Dr. Pereira: In some instances for small tumors of the liver, kidneys or even lung, MIT has already replaced surgery and is also considered in the international guidelines, e.g. liver cancer, metastatic colorectal cancer or kidney cancers.
DocCheck: Which method do you think offers the most potential to be further developed?
Dr. Pereira: There are mainly two: intraarterial treatment since liver tumors have an arterial blood supply and thermal ablation, probably combined with immunotherapies.
DocCheck: With regard to our previous questions, could you sum up the key message of your speech "registries, trials and the evidence base"?
Dr. Pereira: Large Registrie studies reflect the clinical reality and are becoming more and more important. Moreover these studies allow a faster translation in the clinical routine, providing results in a shorter observation time. They are more cost effective, and at least less monitors by the industry.
We say Thank you for your time and for this interview!
Any questions? Just send us an email: email@example.com or post a comment!